Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Equities researchers at Zacks Research decreased their Q1 2024 EPS estimates for Gilead Sciences in a report released on Tuesday, April 23rd. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings of ($1.42) per share for the quarter, down from their prior […]
Parkside Financial Bank & Trust raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,063 shares of the biopharmaceutical company’s stock after acquiring an additional 165 shares […]
Parkside Financial Bank & Trust grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 3,063 shares of the biopharmaceutical company’s stock after purchasing an additional 165 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Gilead Sciences were worth $248,000 […]
Illinois Municipal Retirement Fund lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 24.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 239,358 shares of the biopharmaceutical company’s stock after selling 79,102 shares during the quarter. Illinois Municipal Retirement […]
OLD National Bancorp IN lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 3.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,718 shares of the biopharmaceutical company’s stock after selling 802 shares during the quarter. OLD […]